Massachusetts Financial Services Co. MA Takes $2.40 Million Position in Hims & Hers Health, Inc. (NYSE:HIMS)

Massachusetts Financial Services Co. MA acquired a new stake in shares of Hims & Hers Health, Inc. (NYSE:HIMS) during the 3rd quarter, Holdings Channel.com reports. The institutional investor acquired 130,017 shares of the company’s stock, valued at approximately $2,395,000.

Several other institutional investors have also recently modified their holdings of HIMS. Nisa Investment Advisors LLC grew its position in Hims & Hers Health by 679.2% during the 2nd quarter. Nisa Investment Advisors LLC now owns 1,839 shares of the company’s stock worth $37,000 after acquiring an additional 1,603 shares during the last quarter. Quest Partners LLC grew its position in Hims & Hers Health by 5,944.1% during the 2nd quarter. Quest Partners LLC now owns 3,566 shares of the company’s stock worth $72,000 after acquiring an additional 3,507 shares during the last quarter. CWM LLC grew its position in Hims & Hers Health by 21.4% during the 3rd quarter. CWM LLC now owns 5,982 shares of the company’s stock worth $110,000 after acquiring an additional 1,054 shares during the last quarter. Van ECK Associates Corp bought a new position in Hims & Hers Health during the 2nd quarter worth approximately $111,000. Finally, Amalgamated Bank grew its position in Hims & Hers Health by 55.9% during the 2nd quarter. Amalgamated Bank now owns 6,566 shares of the company’s stock worth $133,000 after acquiring an additional 2,354 shares during the last quarter. 63.52% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

Several equities analysts recently issued reports on HIMS shares. Needham & Company LLC started coverage on Hims & Hers Health in a research report on Thursday, August 22nd. They set a “buy” rating and a $24.00 price target on the stock. Imperial Capital lowered Hims & Hers Health from an “outperform” rating to an “in-line” rating in a research report on Friday, August 9th. Deutsche Bank Aktiengesellschaft increased their price objective on Hims & Hers Health from $23.00 to $27.00 and gave the stock a “hold” rating in a report on Wednesday, November 6th. TD Cowen reiterated a “buy” rating and issued a $28.00 price objective on shares of Hims & Hers Health in a report on Wednesday, November 20th. Finally, Canaccord Genuity Group increased their price objective on Hims & Hers Health from $24.00 to $28.00 and gave the stock a “buy” rating in a report on Tuesday, November 5th. One analyst has rated the stock with a sell rating, eight have assigned a hold rating and seven have given a buy rating to the company’s stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Hold” and a consensus target price of $20.71.

Insider Buying and Selling at Hims & Hers Health

In other Hims & Hers Health news, insider Soleil Boughton sold 2,343 shares of Hims & Hers Health stock in a transaction on Tuesday, November 26th. The stock was sold at an average price of $29.90, for a total transaction of $70,055.70. Following the completion of the transaction, the insider now owns 165,254 shares in the company, valued at approximately $4,941,094.60. The trade was a 1.40 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CEO Andrew Dudum sold 188,888 shares of Hims & Hers Health stock in a transaction on Tuesday, September 3rd. The stock was sold at an average price of $14.56, for a total value of $2,750,209.28. Following the completion of the sale, the chief executive officer now directly owns 33,502 shares of the company’s stock, valued at approximately $487,789.12. The trade was a 84.94 % decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 1,153,519 shares of company stock worth $24,486,721. 17.71% of the stock is owned by insiders.

Hims & Hers Health Stock Down 2.2 %

HIMS opened at $30.67 on Wednesday. The stock has a market cap of $6.70 billion, a PE ratio of 69.73 and a beta of 1.06. The business has a 50 day moving average of $20.85 and a 200-day moving average of $19.44. Hims & Hers Health, Inc. has a 52 week low of $8.09 and a 52 week high of $31.68.

Hims & Hers Health (NYSE:HIMS) last released its earnings results on Monday, November 4th. The company reported $0.32 EPS for the quarter, beating analysts’ consensus estimates of $0.06 by $0.26. The company had revenue of $401.56 million during the quarter, compared to analysts’ expectations of $382.20 million. Hims & Hers Health had a return on equity of 10.97% and a net margin of 8.19%. The firm’s revenue for the quarter was up 77.1% compared to the same quarter last year. During the same quarter last year, the business posted ($0.04) EPS. Equities analysts anticipate that Hims & Hers Health, Inc. will post 0.29 EPS for the current year.

Hims & Hers Health Company Profile

Hims & Hers Health, Inc operates a telehealth platform that connects consumers to licensed healthcare professionals in the United States, the United Kingdom, and internationally. The company offers a range of curated prescription and non-prescription health and wellness products and services available to purchase on its websites and mobile application directly by customers.